Dr. Matthew D. Cheney
Claim this profileMaine Medical Center- Scarborough Campus
Studies Parotid Gland Cancer
Studies Breast Cancer
22 reported clinical trials
60 drugs studied
Area of expertise
1Parotid Gland Cancer
Stage IV
Stage I
Stage II
2Breast Cancer
Stage II
Stage I
HER2 negative
Affiliated Hospitals
Clinical Trials Matthew D. Cheney is currently running
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
More about Matthew D. Cheney
Clinical Trial Related5 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Matthew D. Cheney has experience with
- Radiation Therapy
- Intensity-Modulated Radiation Therapy
- Cisplatin
- Fluorouracil
- Nivolumab
- Bicalutamide
Breakdown of trials Matthew D. Cheney has run
Parotid Gland Cancer
Breast Cancer
Prostate Adenocarcinoma
Cervical Adenocarcinoma
Prostatic Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Matthew D. Cheney specialize in?
Is Matthew D. Cheney currently recruiting for clinical trials?
Are there any treatments that Matthew D. Cheney has studied deeply?
What is the best way to schedule an appointment with Matthew D. Cheney?
What is the office address of Matthew D. Cheney?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.